Erchen decoction combined with Sanziyangqin decoction for chronic obstructive pulmonary disease

Abstract

Introduction: chronic obstructive pulmonary disease (COPD) is 1 of the leading causes of morbidity and mortality worldwide; its economic and social burdens are substantial and increasing. Recent years, an increasing number of study has shown the promising advantage of Erchen decoction (ECD) combined with sanziyangqin decoction (SZYQD) in treating COPD. However, due to the lack of evidence, there is no specific method or suggestion, so it is necessary to provide a protocol for a systematic review on ECD combined with SZYQD for COPD and provide effective evidence for further clinical use. Methods and analysis: We will conduct a Computerized literature searches in the following databases: PubMed, MEDLINE, EMBASE, Cochrane Library, China national information network, China biomedical literature database (CBM), Chinese Scientific Journals Database and wanfang database, from their inception to June 2020, without restrictions of language. Study selection, data collection, and evaluation of the quality of evidence will be performed by 2 researchers independently, risk of bias of the meta-analysis will be evaluated based on the Cochrane Handbook for Systematic Reviews of Interventions. All data analysis will be conducted by data statistics software Review Manager V.5.3. and Stata V.12.0. Results: This study will systematically evaluate the effectiveness and safety of ECD combined with SZYQD for COPD. The results will be published in a peer-reviewed journal. Conclusion: This study will provide evidence from the current published RCTs of whether ERD combined with SZYQD is an effective and safe intervention for COPD. Ethics and dissemination: This study is a systematic review, the outcomes are based on the published evidence. In this study, no individual data from participants will be involved, so ethics approval is not required. Open Science Framework(OSF)registration number: August 19, 2020; osf.io/zxm24.

Effect of Yijin-Tang, an Oriental Traditional Formula, on Allergic Responses Using an Ovalbumin-Induced Murine Asthma Model

“…Antiasthmatic effects of YTE observed in this study were supported by various previous studies [ 11 , 12 , 16 ]. The crude herbs that make up YTE have been shown to have anti-inflammatory and antioxidant properties in various research studies [ 12 – 15 ].…”

“…Owing to this, we predicted that Yijintang would be effective in treating asthma. Moreover, a systematic review and meta-analysis reported that Yijin-tang may be used in the treatment of respiratory diseases [16].…”

“…Owing to this, we predicted that Yijin-tang would be effective in treating asthma. Moreover, a systematic review and meta-analysis reported that Yijin-tang may be used in the treatment of respiratory diseases [ 16 ]. Therefore, we explored the curative effects of Yijin-tang using an ovalbumin- (OVA-) induced asthma model, based on the antioxidant and anti-inflammatory properties of the herb.…”

Erchen Decoction Alleviates High-Fat Diet + AOM/DSS-Induced CRC by Ameliorating Cholesterol-Bile Acid Metabolism Disorder through Regulating FXR and the Gut Microbiota

“…According to recent reports, ECD can effectively treat hyperlipidemia and is widely used in clinical and basic research to ameliorate the metabolic abnormalities of a high-fat diet [32,33]. Moreover, ECD can be combined with other decoctions, such as Huiyanzhuyu decoction to induce apoptosis of laryngeal squamous cell carcinoma cells, Linguizhugan decoction to ameliorate hepatic insulin resistance, and Sanziyangqin decoction for chronic obstructive pulmonary disease, to demonstrate cancer suppression [34][35][36][37][38]. Our study con rmed the antitumor effect of ECD on high-fat diet mice and further explored its mechanism in the progression from cholesterol disorder to abnormal bile acid metabolism and its interaction with the intestinal ora.…”

Erchen Decoction regulates AMPK pathway in the treatment of metabolic syndrome induced by second-generation antipsychotics based on network pharmacology and molecular docking strategy

“…The prescription consists of Pinellia Ternata (BX) (250 g), Exocarpium Citri Rubrum (JH) (250 g), Poria Cocos (FL) (150 g), and Radix et Rhizoma Glycyrrhizae (GC) (75 g). Relevant studies have shown that ECD has a certain effect on treating metabolic diseases such as hyperlipidemia, diabetes, atherosclerosis, and metabolic syndrome [11][12][13], digestive diseases such as non-alcoholic fatty liver [14], and respiratory diseases [15]. Additionly, ECD can improve both the metabolic syndrome and mental symptoms of a psychopath with schizophrenia [16,17].…”